Attached files

file filename
EX-10 - EXHIBIT 10.1 - OMNI BIO PHARMACEUTICAL, INC.ex10-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

January 1, 2014

 

 

Omni Bio Pharmaceutical, Inc.

(Exact name of registrant as specified in its charter)

 

Colorado

000-52530

 20-8097969

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

 

 

5350 South Roslyn, Suite 430, Greenwood Village, CO

80111

(Address of principal executive offices)

(Zip Code)

 
 

(303) 867-3415

(Registrant’s telephone number, including area code)

 
 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

  

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 1, 2014, Omni Bio Pharmaceutical, Inc. (the “Company”) and Bruce E. Schneider, Chief Executive Officer of the Company, entered into an Amendment to Employment Agreement (the “Amendment”), pursuant to which the employment agreement between the Company and Dr. Schneider was amended to (i) extend the term of the employment agreement by one year, (ii) defer $5,000 per month of Dr. Schneider’s base salary until the Company raises additional financing of at least $1.5 million, and (iii) to formalize the anti-dilution feature related to certain warrants previously granted to Dr. Schneider by the Company.

 

The foregoing description of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment attached hereto as Exhibit 10.1, which is incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

     

(d) Exhibits.

 

10.1

Amendment to Employment Agreement between Omni Bio Pharmaceutical, Inc. and Bruce E. Schneider dated January 1, 2014.

 

 
 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Omni Bio Pharmaceutical, Inc.

 

 

Date: January 6, 2014

 

 

By: /s/ Robert C. Ogden     

Robert C. Ogden

Chief Financial Officer

 

 
 

 

 

Exhibit Index

 

                                                       

 

Exhibit No.   Description
     

10.1

 

Amendment to Employment Agreement between Omni Bio Pharmaceutical, Inc. and Bruce E. Schneider dated January 1, 2014.